Clinical Trial

Plan Development for Giving Teclistamab in the Outpatient Setting

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2025 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-01; most recent amendment 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2025-12-02
Trial Details
NCT Number NCT06251076
Lead Sponsor University Health Network, Toronto
Collaborators: Janssen Inc.
Conditions Multiple Myeloma, Relapsed Cancer, Refractory Cancer
Enrollment 15 participants
Start Date 2024-11-19
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-10